NCT01585207View on ClinicalTrials.gov

Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Tourette's Disorder
Interventions
DRUG

vigabatrin

3 tablets, bid for 8 weeks

Trial Locations (1)

10029

Tics and Tourette's Clinical and Research Program, New York

All Listed Sponsors
lead

Barbara J. Coffey

OTHER

NCT01585207 - Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder | Biotech Hunter | Biotech Hunter